Oxford Immunotec Global PLC - Ordinary Shares (OXFD): Price and Financial Metrics
OXFD Price/Volume Stats
| Current price | $21.99 | 52-week high | $23.11 |
| Prev. close | $21.98 | 52-week low | $8.37 |
| Day low | $21.97 | Volume | 808,500 |
| Day high | $21.99 | Avg. volume | 1,099,251 |
| 50-day MA | $21.00 | Dividend yield | N/A |
| 200-day MA | $15.28 | Market Cap | 570.90M |
OXFD Stock Price Chart Interactive Chart >
Oxford Immunotec Global PLC - Ordinary Shares (OXFD) Company Bio
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The company was founded in 2002 and is based in Abingdon, the United Kingdom.
Latest OXFD News From Around the Web
Below are the latest news stories about Oxford Immunotec Global PLC that investors may wish to consider to help them evaluate OXFD as an investment opportunity.
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 InfectionOxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test. |
PerkinElmer, Inc. -- Moody's assigns Baa3 rating to PerkinElmer's notes offeringRating Action: Moody's assigns Baa3 rating to PerkinElmer's notes offeringGlobal Credit Research - 04 Mar 2021New York, March 04, 2021 -- Moody's Investors Service, ("Moody's") assigned a Baa3 rating to the proposed offering of senior unsecured 10- and 30-year notes of PerkinElmer, Inc. ("PerkinElmer"). There are no changes to Moody's existing ratings of PerkinElmer including the Baa3 senior unsecured long-term rating. The acquisition slightly increases PerkinElmer's financial leverage to close to 3.0x, up from 2.5x in the last twelve months to September 30, 2020. |
Lifshitz Law Firm, P.C. Announces Investigation of CHNG, MGLN, OBLN, and OXFDNEW YORK, NY / ACCESSWIRE / February 14, 2021 / Lifshitz Law Firm, P. (NASDAQ:CHNG)Lifshitz Law Firm, P. |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates CUB, CRHM, GLUU, OXFD, OBLN; Shareholders Are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
Oxford signs MOU with Green Cross Medical for T-SPOT Discovery SARS-CoV-2 kitOxford Immunotec (OXFD) announces it has worked with Green Cross Medical Science South Korea (GC MS) to enter into an MOU to market the research use only T-SPOT Discovery SARS-CoV-2 kit in South Korea.Under the agreement, GC MS will market and sell the product with Oxford Immunotec Korea providing overall support for the T-SPOT Discovery SARS-CoV-2... |
OXFD Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 35.24% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 5.21% |
| 2019 | 29.89% |
Continue Researching OXFD
Want to do more research on Oxford Immunotec Global PLC's stock and its price? Try the links below:Oxford Immunotec Global PLC (OXFD) Stock Price | Nasdaq
Oxford Immunotec Global PLC (OXFD) Stock Quote, History and News - Yahoo Finance
Oxford Immunotec Global PLC (OXFD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...